Search clinical trials for: YY-162

Total 2931 results

Yuyu Pharma, Inc.

Completed

Efficacy and Safety Study of Combination of Ginkgo Extract and Ginseng Extract(YY-162)in Children With ADHD (yuyu)

Mental Disorders

Korea, Republic of
Shanghai YingLi Pharmaceutical Co. Ltd.

Unknown

A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies

Mantle Cell Lymphoma | Marginal Zone Lymphoma | Lymphoplasmacytic Lymphoma | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma
Yuyu Pharma, Inc.

Completed

Efficacy and Safety Study of Combination of Ginkgo Extract and Ginseng Extract in Children With ADHD(Attention Deficit Hyperactivity Disorder) (ADHD)

Mental Disorders

Korea, Republic of
Yuyu Pharma, Inc.

Completed

A Dose-Finding, Efficacy and Safety Study of YY-351 in Patients With Type 2 Diabetes

Diabetes

Korea, Republic of
Shanghai YingLi Pharmaceutical Co. Ltd.

Not yet recruiting

A Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma

PTCL
Shanghai YingLi Pharmaceutical Co. Ltd.

Unknown

A Phase Ib Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

Relapsed or Refractory Peripheral T-Cell Lymphoma

China
Shanghai YingLi Pharmaceutical Co. Ltd.

Not yet recruiting

A National Multicenter, Real-world Study of Linperlisib in the Treatment of Lymphoma

Indolent B-cell Lymphoma
Ruijin Hospital
Tianjin Medical University Cancer Institute and Hospital

Not yet recruiting

Real World Study of Linperlisib for Lymphoma Treatment (MA-LYM-RWS-001)

Focus on the Lymphoma Including B/T-cell Lymphoma

China
Shanghai YingLi Pharmaceutical Co. Ltd.

Not yet recruiting

A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Thymic Cancer

Effectiveness，Safety，Thymic Cancer
Shanghai YingLi Pharmaceutical Co. Ltd.

Unknown

A Study of YY-20394 in Participants With Relapsed/Refractory Follicular Non-Hodgkin's Lymphoma

Lymphoma, Follicular

China
Shanghai YingLi Pharmaceutical Co. Ltd.

Recruiting

A Phase II Study of Linperlisib (YY-20394) in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma

Peripheral T/NK Cell Lymphoma (R/R PTCL)

United States
University of Copenhagen
EC-FP6 (contract number: LHM-CT-2003-503041); Aditech Pharma AB

Completed

The Role of Peptide YY (PYY)Infusions in Inhibiting Food Intake.

Obesity
University of Copenhagen
Aditech Pharma AB

Completed

The Role of Peptide YY (PYY)in Inhibiting Food Intake.

Obesity
Shanghai YingLi Pharmaceutical Co. Ltd.

Unknown

A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Follicular Lymphoma

Follicular Lymphoma
Shanghai YingLi Pharmaceutical Co. Ltd.

Unknown

A Phase I Study of YY-20394 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Gila Therapeutics, Inc.

Completed

A Dose Escalating Study to Assess the Safety and Tolerability of GT-001

Feeding and Eating Disorders

United States
Shanghai YingLi Pharmaceutical Co. Ltd.

Unknown

A Phase I Study of YY-20394 in Patients With B Cell Hematologic Malignancies

B-cell Chronic Lymphocytic Leukemia | B-cell Lymphoma Recurrent

China
Vanda Pharmaceuticals

Completed

VEC-162 Study in Healthy Adult Volunteers in a Model of Insomnia

Insomnia

United States
UniQure Biopharma B.V.

Not yet recruiting

Safety, Tolerability, and Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Amyotrophic Lateral Sclerosis (ALS) Patients With SOD1 Mutations

Amyotrophic Lateral Sclerosis
M.D. Anderson Cancer Center
Array BioPharma

Terminated

MEK Inhibitor 162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy

Leukemia

United States
Vanda Pharmaceuticals

Completed

Safety and Efficacy of VEC-162 on Circadian Rhythm in Healthy Adult Volunteers

Circadian Rhythm Sleep Disorders

United States
Beijing Shenogen Biomedical Co., Ltd
307 Hospital of PLA; Cancer Institute and Hospital, Chinese Academy of Medical... and other collaborators

Completed

The Phase II Study of Icaritin in Patients With Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma (HCC)

China
Vanda Pharmaceuticals

Completed

Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder

Non-24-Hour Sleep-Wake Disorder

United States
Vanda Pharmaceuticals

Completed

VEC-162 Study in Adult Patients With Primary Insomnia

Primary Insomnia

United States
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers

Acute Myeloid Leukemia (AML) | Myelodysplastic Syndrome (MDS) | Chronic Myeloid Leukemia (CML)

United States
Vanda Pharmaceuticals

Active, not recruiting

Safety Study of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder in Blind Individuals With No Light Perception

Non 24 Hour Sleep Wake Disorder

France
Cancer Institute and Hospital, Chinese Academy...
Beijing Shenogen Biomedical Co., Ltd

Completed

A Phase Ib Study to Assess Safety and Efficacy of Oral Icaritin in Advanced Solid Tumors

Solid Tumors

China
Vanda Pharmaceuticals

Completed

Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception

Non-24-Hour Sleep-Wake Disorder

United States
Vanda Pharmaceuticals

Completed

Pharmacokinetics of Tasimelteon in Subjects With Renal Impairment and Matched Control Subjects With Relatively Normal Renal Function

Renal Impairment

United States
Biocad

Completed

The BCD-089 (aIL6R) in Patients With Active Rheumatoid Arthritis (AURORA)

Seropositive RA

Russian Federation, Belarus
Vanda Pharmaceuticals

Completed

Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder

Non-24-Hour Sleep-Wake Disorder

United States, Germany
Amgen

Completed

Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) Bisphosphonates

Bone Metastases in Men With Hormone-Refractory Prostate Cancer | Bone Metastases in Subjects With Advanced Breast Cancer | Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma
Amgen

Completed

A Randomized, Double-blind, Placebo-controlled, Dose Response Study of AMG 162 (Denosumab) in Japanese Postmenopausal Osteoporotic Subjects

Osteoporosis
Vanda Pharmaceuticals

Completed

Effects of Smoking, Age and Body Size on Pharmacokinetics, Safety and Tolerability on Tasimelteon in Healthy Subjects

Healthy Volunteers

United States
EMS

Withdrawn

Efficacy of Fixed-doses of Antihypertensive and Statin Drugs

Hypertension | Dyslipidemia
Neothetics, Inc

Completed

A Dose-ranging, Study of the Safety and Efficacy of Subcutaneous Injections of LIPO-102 Compared With Placebo for the Reduction of Abdominal Subcutaneous Adiposity

Weight

United States
Chonbuk National University Hospital

Completed

Efficacy of an Extract of Concentrated Korean Red Ginseng for Preventing Upper Respiratory Tract Infections

Healthy Subjects

Korea, Republic of
Yangshengtang Co., Ltd

Not yet recruiting

A Clinical Study of 162 in Subjects With Chronic Hepatitis B Virus Infection

Chronic Hepatitis B Virus Infection
Yangshengtang Co., Ltd
Syneos Health

Completed

Phase 1 Study of 162, a Novel Neutralizing Antibody Targeting Hepatitis B Surface Antigen, in Healthy Adult Subjects

Chronic Hepatitis B

Australia
Bayer

Completed

To Evaluate Eye Installation-Tear Free

Sunscreening Agents

United States
Taisho Pharmaceutical R&D Inc.

Completed

First-in-Human Study With Single and Multiple Doses of TS-161 in Healthy Participants

Healthy Volunteers

United States
M.D. Anderson Cancer Center
Array BioPharma

Terminated

An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)

Leukemia

United States
Cancer Institute and Hospital, Chinese Academy...
Beijing Shenogen Biomedical Co., Ltd

Unknown

Phase I Study of Novel Estrogen Receptor(ER) a36 Modifier Icaritin in Advanced Breast Cancer Patients

Metastatic Breast Cancer

China
Roswell Park Cancer Institute
Amgen

Completed

Denosumab in Treating Patients With Bone Loss Due to Donor Stem Cell Transplant

Osteoporosis | Osteopenia | Allogeneic Hematopoietic Stem Cell Transplantation Recipient

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
Abbott

Completed

Pharmacokinetic Study of ABT-126 in Stable Subjects With Schizophrenia

Schizophrenia

United States
CinDome Pharma, Inc.

Completed

A Phase 2 Study of CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis

Gastroparesis

United States
Terumo Europe N.V.

Recruiting

Holmium-166 Transarterial Radioembolization in Unresectable, Early Stage Hepatocellular Carcinoma. (HOMIE-166)

Hepatocellular Carcinoma

Germany
Beijing Shenogen Biomedical Co., Ltd
The First Affiliated Hospital with Nanjing Medical University; Guilin Medical... and other collaborators

Unknown

The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma Subjects

Advanced HBV-Related Hepatocellular Carcinoma (HCC)

China
Northwestern University
National Cancer Institute (NCI); Amgen

Terminated

Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells

Stage IV Breast Cancer | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Positive | Breast Carcinoma Metastatic in the Bone | Circulating Tumor Cell Count

United States

Search clinical trials for: YY-162

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in New Zealand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations